Semaglutide research is moving beyond “how much weight did they lose?” to “what did they lose?” 🧬
An eight-week study in obese non-human primates tested semaglutide alongside IBIO-610, an experimental antibody targeting Activin E.
The body-composition results:
🔹 Semaglutide alone: lean mass accounted for 22% of the weight lost.
🔹 Semaglutide + IBIO-610: lean mass accounted for 6% of the weight lost.
Fat accounted for 77% and 93% of the weight lost, respectively.
Those percentages describe the composition of the lost weight—not the percentage of each animal’s muscle that disappeared.
The distinction matters. Lean mass includes muscle, but also water, organs and other tissues. These figures alone do not establish preserved strength or physical function.
There were just six animals per group, and this was a company-reported preclinical study. Human results are still ahead.
Still, the finding gives researchers a concrete direction to investigate: shifting more of the weight reduction toward fat while limiting lean-mass loss.
IBIO-610 is an antibody, not another peptide. The peptide in this combination is semaglutide.